2P4 Stock Chart & Stats
€0.16
>-€0.01(-2.86%)
At close: 4:00 PM EST
€0.16
>-€0.01(-2.86%)
Day’s Range― - ―
52-Week Range€0.10 - €0.19
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€77.82M
Enterprise Value€457.64
Total Cash (Recent Filing)€32.84M
Total Debt (Recent Filing)€10.24M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding495,108,900
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe commercial setup has been strengthened in the U.S. by adding sales staff and medical liaisons to drive the demand for NGAL products.
Revenue GrowthRevenue grew 17% and is expected to grow 24-66%, driven by increased ProNephro AKI (NGAL) sales.
Sales MomentumThe company has received the first standing order from a U.S. hospital with an annual value of over USD 200K.
Bears Say
Capital RequirementsThe company may need to raise additional capital to fund operations within the next 12 months.
Regulatory Approval TimelineProNephro AKI study for adult use is underway; FDA submission expected in 2026, potentially delaying market expansion.
BioPorto AS News
2P4 FAQ
What was BioPorto AS’s price range in the past 12 months?
BioPorto AS lowest stock price was €0.10 and its highest was €0.19 in the past 12 months.
What is BioPorto AS’s market cap?
BioPorto AS’s market cap is €77.82M.
When is BioPorto AS’s upcoming earnings report date?
BioPorto AS’s upcoming earnings report date is Aug 20, 2026 which is in 24 days.
How were BioPorto AS’s earnings last quarter?
Currently, no data Available
Is BioPorto AS overvalued?
According to Wall Street analysts BioPorto AS’s price is currently Overvalued.
Does BioPorto AS pay dividends?
BioPorto AS does not currently pay dividends.
What is BioPorto AS’s EPS estimate?
BioPorto AS’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioPorto AS have?
BioPorto AS has 495,108,900 shares outstanding.
What happened to BioPorto AS’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioPorto AS?
Currently, no hedge funds are holding shares in DE:2P4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioPorto AS
BioPorto A/S is a Danish in-vitro diagnostics specialist, supplying biomarker tests, research tools, and antibodies to medical professionals and scientists worldwide, with operations across Europe, North America, and Asia. Among its offerings is the neutrophil gelatinase-associated lipocalin (NGAL) test, a precise quantitative particle-enhanced turbidimetric immunoassay designed for use on automated chemistry analyzers. The company further provides monoclonal antibodies essential for scientific, pharmaceutical, and clinical investigations. Additionally, BioPorto produces enzyme-linked immunosorbent assay (ELISA) kits and a versatile rapid assay device tailored for custom lateral flow assay development. Established in 1917, the company is headquartered in Hellerup, Denmark.